Andrew Shyu, MD
Ophthalmology · Wilmington, DENPI 1275066599
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $500, more than ten times the $37 reported in 2021. That places this record below the midpoint for ophthalmology clinicians in DE, where the typical reported total is $1,099.
Across 43 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$259
- AbbVie$181
- Sun Pharmaceutical Industries Inc.$133
- Harrow Eye, LLC$84
- Bausch & Lomb Americas Inc.$79
- Dompe US, Inc.$64
- plus $300 from 8 others
What the payments were for
- Food & beverage$1,07798%
- Other$222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 10 | $259 |
| AbbVie(2 entities) | 8 | $181 |
| Sun Pharmaceutical Industries Inc. | 4 | $133 |
| Harrow Eye, LLC | 3 | $84 |
| Bausch & Lomb Americas Inc. | 4 | $79 |
| Dompe US, Inc. | 2 | $64 |
| Rxsight Inc | 2 | $61 |
| Oyster Point Pharma, Inc. | 2 | $55 |
| Amgen(2 entities) | 2 | $47 |
| Merz Pharmaceuticals, LLC | 1 | $40 |
| Carl Zeiss Meditec USA, Inc. | 2 | $40 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $26 |
| LKC Technologies, Inc. | 1 | $21 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$1,099 in reported general payments places this provider in the 50th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 47 | $38,693 |
| LumiganBimatoprost | 48 | $23,973 |
| XiidraLifitegrast | 19 | $12,812 |
| Restasis MultidoseCyclosporine | 20 | $12,580 |
| Latanoprost | 555 | $5,282 |
| Travoprost | 18 | $3,404 |
| Prednisolone Acetate | 84 | $2,738 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 151 | $2,340 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $1,715 |
| Timolol Maleate | 141 | $1,566 |
| Brimonidine Tartrate | 55 | $1,111 |
| Ketorolac Tromethamine | 51 | $903 |
| Doxycycline Hyclate | 46 | $857 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 78 | $851 |
| ValacyclovirValacyclovir Hcl | 16 | $699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose | $181 | $75,247115 claims |
| Bausch & Lomb Americas Inc.Xiidra | $79 | $12,81219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 49 ophthalmology providers in Delaware.
Other ophthalmology in Wilmington
- Jeffrey MinkovitzWilmington$7K
- Heather DealyWilmington$6K
- Stewart SmithWilmington$6K
- Richard SherryWilmington$5K
- Michael BrosmanWilmington$5K
- Brian ToussaintWilmington$2K
- Sean ConsidineWilmington$2K
- Tabassum AliWilmington$2K
- Paula KoWilmington$2K
- Harry LebowitzWilmington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.